KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Gross Margin (2017 - 2025)

Historic Gross Margin for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to 64.82%.

  • Aquestive Therapeutics' Gross Margin fell 24200.0% to 64.82% in Q3 2025 from the same period last year, while for Sep 2025 it was 231.04%, marking a year-over-year increase of 1630100.0%. This contributed to the annual value of 1673.02% for FY2024, which is 17318300.0% down from last year.
  • Aquestive Therapeutics' Gross Margin amounted to 64.82% in Q3 2025, which was down 24200.0% from 54.4% recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Gross Margin high stood at 110.12% for Q4 2024, and its period low was 123.3% during Q2 2021.
  • Over the past 5 years, Aquestive Therapeutics' median Gross Margin value was 63.1% (recorded in 2023), while the average stood at 53.35%.
  • As far as peak fluctuations go, Aquestive Therapeutics' Gross Margin skyrocketed by 4845000bps in 2021, and later crashed by -230800bps in 2025.
  • Aquestive Therapeutics' Gross Margin (Quarter) stood at 69.62% in 2021, then decreased by -28bps to 50.34% in 2022, then grew by 16bps to 58.49% in 2023, then soared by 88bps to 110.12% in 2024, then tumbled by -41bps to 64.82% in 2025.
  • Its Gross Margin was 64.82% in Q3 2025, compared to 54.4% in Q2 2025 and 58.12% in Q1 2025.